Serotype Distribution of Streptococcus pneumoniae causing Invasive Pneumococcal Disease at Bambino Gesù Children's Hospital in Rome: Is It Time for a New Vaccine?
21 December 2016
05 November 2017
02 January 2018 (online)
Diseases caused by Streptococcus pneumoniae are mostly preventable infections by current immunization programs. The objective of this study was to evaluate the impact of the introduction of the heptavalent and the 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13) on the burden of pneumococcal disease and on the serotype distribution of S. pneumoniae causing invasive pneumococcal diseases (IPDs) in the pediatric age over a 5-year study (from January 2008 till December 2012). We observed a decrease in IPD rate in children after PCV13 introduction despite increases in nonvaccine serotype (NVS) rates in 2011. Nevertheless, from 2012, an increase in IPD rates due to non-PCV13 serotypes was observed.
- 1 McIntosh ED, Fritzell B, Fletcher MA. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiol Infect 2007; 135 (04) 644-656
- 2 Gherardi G, Fallico L, Del Grosso M. , et al. Antibiotic-resistant invasive pneumococcal clones in Italy. J Clin Microbiol 2007; 45 (02) 306-312
- 3 Gherardi G, D'Ambrosio F, Visaggio D, Dicuonzo G, Del Grosso M, Pantosti A. Serotype and clonal evolution of penicillin-nonsusceptible invasive Streptococcus pneumoniae in the 7-valent pneumococcal conjugate vaccine era in Italy. Antimicrob Agents Chemother 2012; 56 (09) 4965-4968
- 4 American Academy of Pediatrics Committee on Infectious Disease. Policy statement: recommendations for the prevention of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106: 362-366
- 5 Centers for Disease Control and Prevention (CDC). Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008. MMWR Morb Mortal Wkly Rep 2008; 57 (42) 1148-1151
- 6 Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49 (RR-9): 1-35
- 7 Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine-United States, 2007. MMWR Morb Mortal Wkly Rep 2010; 59 (09) 253-257
- 8 Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005; 116 (03) e408-e413
- 9 Flasche S, Van Hoek AJ, Sheasby E. , et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 2011; 8 (04) e1001017 doi: 10.1371/journal.pmed.1001017
- 10 Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010; 14 (03) e197-e209
- 11 van der Linden M, Weiß S, Falkenhorst G, Siedler A, Imöhl M, von Kries R. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 2012; 30 (40) 5880-5885